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Objective: To benchmark the immunogenicity of pneumococcal conjugated vaccine (PCV-13) versus pneu-
mococcal polysaccharide vaccine (PPV-23) in haemodialysis patients pre-vaccinated or not with PPV-23.
Methods: The study is a longitudinal quasi-experimental phase IV study in chronic haemodialysis pa-
tients aged 50 years. Total (ELISA) and functional (opsonophagocytic assay) antibodies after pneu-
mococcal vaccination were quantiﬁed at baseline, and after 28 and 365 days. Of 201 eligible patients, 155
were included. Patients were divided in four groups. PPV-23 naive patients were randomized to PPV-23
(40) or PCV-13 (40) vaccination. PPV-23-pre-vaccinated patients were categorized as being vaccinated
more (40) or less (35) than 4 years before the study and all received PCV-13.
Results: Patients among the four groups had a signiﬁcant ELISA antibody response for most serotypes
that remained signiﬁcant up to day 365 versus baseline. In PPV-23-naive patients, ELISA antibody titres
were signiﬁcantly higher among PCV-13 versus PPV-23 recipients for six serotypes (1.85e2.34-fold) after
28 days, and remained signiﬁcantly higher for one serotype (6A, 1.57-fold) after 365 days. Following PCV-
13 vaccination, increase in ELISA antibody titres was signiﬁcantly higher among PPV-23-naive versus
PPV-23-pre-vaccinated patients for 12 serotypes after 28 days (1.68e7.74-fold) and remained signiﬁ-
cantly higher in ten serotypes (1.44e3.29-fold) after 365 days.
Conclusion: Immune response after PPV-23 and PCV-13 remains signiﬁcant for at least 1 year in non-
PPV-23-pre-vaccinated patients. Among vaccine-naive haemodialysis patients PCV-13 seems more
immunogenic than PPV-23. Immune response to PCV-13 is weaker in PPV-23-pre-vaccinated compared
with vaccine-naive patients. S.J. Vandecasteele, Clin Microbiol Infect 2018;24:65
© 2017 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious
Diseases.Introduction
Pneumococcal polysaccharide vaccines induce a T-cell-inde-
pendent B-cell response [1], but are poorly immunogenic in young
children, the elderly and immunocompromised patients [2].
Pneumococcal polysaccharide vaccines (PPV) decrease the inci-
dence of invasive pneumococcal disease, but their impact on
non-invasive pneumococcal disease is less clear [1]. Pneumo-
coccal conjugated vaccines (PCV) were developed to improveof Nephrology and Infectious
e (S.J. Vandecasteele).
lf of European Society of Clinical Mpneumococcal vaccine immunogenicity. PCV induce both a T-cell
and B-cell response and an immunological memory. PCV-13 covers
61% of invasive pneumococcal disease strains in Belgium [3]. Uni-
versal PCV-7 childhood vaccination was introduced in 2004 in
Belgium, and replaced by the PCV-13 in 2011. In a large, prospective,
population-based placebo-controlled study in people >65 years of
age (CaPiTa trial), PCV-13 vaccination was associated with a 45%
decrease in vaccine-type pneumonia and a 75% decrease in vaccine-
type invasive pneumococcal disease, without decreasing overall
pneumonia incidence and mortality [4].
Pneumonia incidence in patients with end-stage renal disease
(ESRD) is 27.9/100 person-years, with a 1 year survival rate of onlyicrobiology and Infectious Diseases.
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patients with ESRD are scarce and hampered by multiple meth-
odological issues. Guidelines recommending pneumococcal vacci-
nation in patients with ESRD are mainly based on extrapolations
from the general population in conjunction with population-
speciﬁc epidemiological and serological data [1]. Two large retro-
spective cohort studies in patients undergoing haemodialysis
demonstrated a hazard rate for mortality of 0.84 [9] to 0.94 [10] for
pneumococcal vaccination alone, and of 0.71 [9] to 0.73 [10] for
combined pneumococcal and ﬂu vaccination. This beneﬁcial cor-
relation does not, however, prove causality. Eleven studies with
polysaccharide vaccines (only three with PPV-23) were performed
in patients with ESRD [11]. Most of these trials were small (only two
with >33 patients), non-randomized and had a limited follow up of
only 6e12 months [1,11e13]. Overall, a serological response to at
least some of the serotypes was documented in the majority of
patients, which tended to be lower and more rapidly waning than
in healthy controls [1,11]. One-ﬁfth of vaccinated patients devel-
oped pneumococcal disease in the long term [1]. Two small trials
studied conjugated pneumococcal vaccines. In the ﬁrst, more than
half of 48 children vaccinated with PCV-7 were non-responders,
deﬁned as the absence of a more than four-fold rise in antibody
levels for at least ﬁve serotypes [14]. In the second, PCV-13 vacci-
nation in 25 adult dialysis patients resulted in a certain antibody
response at 2 months that grossly disappeared after 1 year [15].
The current study aimed to benchmark the immunogenicity of
PCV-13 vaccine compared with the PPV-23 vaccine in patients with
ESRD treated with chronic haemodialysis that were pre-vaccinated,
or not, with PPV-23.
Materials and methods
Trial design
The study is a longitudinal quasi-experimental phase IV study in
chronic haemodialysis patients aged 50 years benchmarking im-
mune response to pneumococcal vaccination (Fig. 1). All eligible
patients were classiﬁed according to their PPV-23 vaccination status.Fig. 1. Study design and outcome (LOF, lost to foEligible PPV-23-naive patients were randomized according to the
alphabetical order of the ﬁrst letter of their name to vaccinationwith
either PPV-23 (group 1) or PCV-13 (group 2). PPV-23-pre-vaccinated
patients were classiﬁed as vaccinated more (group 3) or less (group
4) than 4 years before the study, and were all vaccinated with PCV-
13. In group 3, patients were selected listed according to the
alphabetical order of their name, and only the 40 ﬁrst patients were
included. Initially a 5-year cut-off was foreseen to differentiate
recent from older PPV-23 vaccination, but this yielded almost no
group 3 patients due to the high 5-yearmortality of dialysis patients.
Participants
Patients were eligible if (a) treated with chronic haemodialysis,
(b) 50 years of age, (c) not pregnant, (d) without immediate life-
threatening conditions, (e) without allergy to the vaccines, (f) with
pneumococcal vaccination status documented in the medical ﬁles,
and (g) gave their informed consent. All patients were treated in
two dialysis centres in Belgium (AZ Sint-Jan Brugge-Oostende AV in
Bruges, Onze Lieve Vrouw Ziekenhuis in Aalst).
Interventions
The PPV-23 vaccine, Pneumo 23™ (Sanoﬁ Pasteur MSD, Brus-
sels, Belgium) contained antigens to 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10,
11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F. The PCV-13
vaccine, Prevenar 13™ (Weyth Lederle Phizer, Louvain-la-Neuve,
Belgium) contained antigens to 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C,
19A, 19F and 23F. All vaccines were administered intramuscularly
on the 24 and 25 of February 2013. Baseline blood samples were
taken on the day of vaccination, at the start of dialysis treatment.
Vaccination was given at the end of the same dialysis treatment,
about 3.5 h later.
Outcomes
The primary endpoint was the ELISA and opsonophagocytic
assay (OPA) antibody response after 4 and 52weeks comparedwithllow up; transplant, kidney transplantation).
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23 and PCV-13 antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F and
23F) and to the PCV13 (6A) speciﬁc serotype 6A were quantiﬁed as
previously described [16,17].
The secondary endpoints were:
(a) Vaccine adverse effects. Patients registered daily sublingual
temperature, analgesic use, fatigue, generalized muscle
aches, headache, and itching, pain, or subjectively reported
decreased mobility in the vaccinated arm for 7 days. Severity
levels were I (present, but easily tolerated), II (interfering
with daily activity) or III (severe or debilitating). Before
vaccination, and on subsequent dialysis sessions (48, 72 and
96 h), trained nurses registered the area of redness, discol-
oration and localized swelling in the vaccinated arm by
placing a transparent sheet with circles of various diameters
(ranging from 1 to 15 cm) on the vaccinated arm. Severity
levels were I (<8 cm), II (8 and <15 cm), and III (15 cm).
(b) Patient mortality and pneumonia (deﬁned as acute respira-
tory illness with a new inﬁltrate on chest X-ray) incidence.
Additional sub-analyses of the primary outcome data compared
differences in antibody response in PPV-23-naive patients after
PCV-13 versus PPV-23 vaccination, differences in antibody
response after PCV-13 vaccination in PPV-23-naive versus PPV-23-
pre-vaccinated patients, and differences in antibody response after
PCV-13 vaccination in patients that were previously vaccinated
with the PPV-23 vaccine >4 years versus <4 years earlier.
Sample size
The study was designed as a benchmark trial. Given the lack of
any information on the effect of PCV-13 vaccination in dialysis
patients, and the absence of a clear single number primary outcome
parameter (geometric mean titre (GMT) for speciﬁc serotype), no
primary power analysis was done.
Statistical methods
Baseline characteristics of patients were summarized according
to the mean and standard deviation (SD), median and interquartileTable 1
Baseline patient characteristics
Group 1
PPV-23-naive
PPV-23 vaccine
Group 2
PPV-23-naive
PCV-13 vaccine
n 40 40
Men, n (%) 23 (57.5%) 25 (62.5%)
Age (years)a 72.4 (13.4) 68.3 (13.9)
Vintage (years)b 2.04 (0.82e4.85) 2.45 (1.41e3.87
Underlying disease, n
Vascular 24 19
Diabetes 9 9
Glomerulonephritis 3 3
Cystic 0 3
Interstitial 2 5
Other 2 1
Laboratory values
Haemoglobin (g/dL)a 10.8 (1.2) 11.0 (1.2)
Urea (mg/dL)a 118.2 (40.8) 127.4 (44.7)
Albumin (g/dL)a 37.3 (4.1) 38.3 (3.5)
Phosphate (meq/L)a 1.63 (0.67) 1.51 (0.44)
C-reactive protein (mg/L)b 7.24 (3.55e16.65) 6.30 (2.92e17.2
Abbreviations: PCV-13, pneumococcal conjugated vaccine; PPV-23, pneumococcal polys
Data are given as.
a mean (SD) or.
b median (P25eP75).
c Signiﬁcance is given according to Fisher's exact test for categorical data or the Kruskrange (P25eP75) or percentages. Their distributionwas statistically
compared between the four groups using Fisher's exact test for
categorical data and the KruskaleWallis test for continuous data.
Patient outcomes and incidences of adverse effects were compared
according to the Fisher's exact test. Antibody responses were
summarized as the GMT by back-transforming (calculating the
antilog) of average log-transformed titres. Equally, two-sided 95%
CIs were constructed by back-transformation of the CIs for the
mean of the logarithmically transformed assay results, computed
using the Student's t distribution. Differences in GMTs between two
groups (or changes in GMTs from baseline to 28 days and from
baseline to 365 days), were expressed as GMT ratios calculated by
back transforming the mean differences between vaccine groups
(or time-points) on the logarithmic scale. GMT ratios were
considered statistically signiﬁcant if their 95% CI did not include the
value 1. Differences in GMT ratios were evaluated according to the
ManneWhitney U test for two independent samples. All analyses
were carried out using SAS software (release 9.4; Cary, NC, USA).Informed consent and institutional review
All patients providedwritten informed consent before inclusion.
The protocol was approved by the Ethical Committee of both hos-
pitals. ClinicalTrials.gov registration number is NCT02492438.Results
Patients
Baseline patient characteristics are summarized in Table 1. From
the 85 eligible PPV-23-naive patients, 40 were randomized to
vaccinationwith PPV-23 (group 1), and 40 to vaccinationwith PCV-
13 (group 2). From the 77 eligible patients that were pre-vaccinated
with PPV-23 >4 years earlier, 40 were selected for PCV-13 vacci-
nation (group 3). Among the 39 eligible patients that were pre-
vaccinated with PPV-23 <4 years earlier, four died between inclu-
sion in the study and start of the study, leaving 35 patients that
were vaccinatedwith PCV-13 (group 4). Patients in the PPV-23-pre-
vaccinated groups 3 and 4 had a higher dialysis vintage, and,Group 3
PPV-23 >4 years
PCV-13 vaccine
Group 4
PPV-23 <4 years
PCV-13 vaccine
p valuec
40 35
17 (42.5%) 23 (65.7%) 0.172
74.8 (8.7) 74.6 (8.2) 0.204
) 3.40 (2.48e5.09) 2.83 (1.46e6.30) 0.030
20 16 0.606
9 11 0.750
4 2 0.976
2 0 0.171
4 1 0.393
1 5 0.172
10.9 (1.0) 10.8 (1.4) 0.795
147.1 (36.6) 144.7 (45.5) 0.008
37.8 (3.1) 37.0 (4.2) 0.543
1.49 (0.30) 1.62 (0.40) 0.834
1) 7.28 (2.65e17.24) 6.30 (1.68e22.08) 0.778
accharide vaccine.
aleWallis test for continuous data.
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residual kidney function.Antibody response after pneumococcal vaccination
Primary endpoint: overall antibody response after 28 and 365 days
compared with baseline (Tables 2 and 3)
For group 1 patients (PPV-23-naive, PPV-23 vaccine), GMT
antibody titres were signiﬁcantly higher for all serotypes at day 28
(ELISA: 1.3- to 6.5-fold; OPA: 3.9- to 40.7-fold), and remained
signiﬁcantly higher for 12 serotypes at day 365 (ELISA: 1.6- to 4.2-
fold; OPA: 1.8- to 11.5-fold). For group 2 patients (PPV-23-naive,
PCV-13 vaccine), GMT antibody titres were signiﬁcantly higher for
all serotypes at day 28 (ELISA: 2.2- to 10.6-fold; OPA: 2.8- to 63.7-
fold), and remained signiﬁcantly higher for 12 serotypes at day
365 (ELISA: 2.1- to 6.0-fold; OPA: 2.5- to 21.5-fold). For group 3
patients (PPV-23 >4 years, PCV-13 vaccine), GMT antibody titres
were signiﬁcantly higher for 12 serotypes at day 28 (ELISA: 1.1- to
2.5-fold; OPA: 1.5- to 7.5-fold), and remained signiﬁcantly higher in
three serotypes with OPA and nine serotypes with ELISA at day 365
(ELISA: 1.3- to 2.0-fold; OPA: 1.6- to 2.3-fold). For group 4 patients
(PPV-23 <4 years, PCV-13 vaccine), GMT antibody titres were
signiﬁcantly higher for 12 serotypes at day 28 (ELISA: 1.4- to 2.7-
fold; OPA: 1.7- to 10.8-fold), and remained signiﬁcantly higher for
nine serotypes with OPA and 12 with ELISA at day 365 (ELISA: 1.6-
to 2.6-fold; OPA: 1.4- to 6.7-fold).Differences in antibody response in PPV-23-naive patients after
PCV-13 versus PPV-23 vaccination (Table 4)
At baseline, antibody titres did not differ among the two groups.
At day 28, GMT of ELISA titres provoked by PCV-13 versus the PPV-
23 were 1.85- to 2.34-fold higher for six serotypes. The GMT of OPATable 2
Antibody response at 4 weeks compared with baseline titres
Group 1
PPV-23-naive þ PPV-23 vaccine
Group 2
PPV-23-naive þ PCV-13 vaccine
N GMT0 GMT4 GMT ratio (95% CI)a N GMT0 GMT4 GMT ratio (95% CI)
ELISA
1 35 0.22 1.40 6.5 (4.1e10.3) 35 0.19 1.80 9.4 (5.3e16.8)
3 27 0.12 0.22 1.9 (1.3e2.6) 30 0.13 0.29 2.2 (1.6e3.1)
4 37 0.09 0.44 4.8 (3.1e7.4) 38 0.09 0.99 10.6 (6.2e18.3)
5 37 1.29 1.63 1.3 (1.1e1.5) 35 1.26 3.71 3.0 (2.0e4.4)
6A 30 0.83 1.23 1.5 (1.1e2.0) 36 0.90 2.66 3.0 (2.0e4.3)
6B 30 0.45 1.60 3.5 (2.4e5.2) 34 0.76 3.37 4.4 (2.7e7.3)
7F 38 0.60 2.15 3.6 (2.6e5.0) 39 0.74 6.08 8.2 (4.5e15.0)
9V 38 0.55 1.48 2.7 (2.1e3.6) 37 0.65 3.24 5.0 (3.2e7.9)
14 37 1.55 6.40 4.1 (2.4e7.0) 39 1.87 10.30 5.5 (3.2e9.5)
18C 37 0.58 2.26 3.9 (2.7e5.6) 39 0.61 3.79 6.2 (3.9e9.8)
19A 38 1.63 3.00 1.8 (1.5e2.3) 38 1.55 5.60 3.6 (2.3e5.6)
19F 38 0.47 1.11 2.4 (1.7e3.3) 35 0.62 2.02 3.2 (2.0e5.3)
23F 37 0.56 1.35 2.4 (1.7e3.4) 36 0.96 3.22 3.3 (2.0e5.4)
OPA
1 35 5.64 45.21 8.0 (4.5e14.4) 35 5.63 55.73 9.9 (5.4e18.2)
3 36 4.48 26.39 5.9 (3.8e9.2) 34 6.21 17.33 2.8 (1.7e4.4)
4 22 7.83 318.76 40.7 (12.2e135.3) 27 5.59 355.89 63.7 (20.9e193.8)
5 35 4.63 18.05 3.9 (2.3e6.5) 36 5.19 72.43 14.0 (6.8e28.8)
6A 32 12.54 225.15 18.0 (7.7e41.8) 34 26.22 746.89 28.5 (11.8e69.1)
6B 21 23.92 355.95 14.9 (5.5e40.3) 28 31.56 675.85 21.4 (7.9e57.8)
7F 36 12.92 243.51 18.9 (8.9e40.0) 31 20.49 559.61 27.3 (11.1e67.3)
9V 30 34.64 309.37 8.9 (3.7e21.4) 23 40.73 401.39 9.9 (3.8e25.6)
14 22 30.10 560.51 18.6 (6.3e55.5) 23 75.15 756.37 10.1 (4.2e23.9)
18C 24 11.87 229.90 19.4 (8.5e44.0) 29 9.80 155.70 15.9 (6.6e38.1)
19A 34 19.08 124.66 6.5 (3.6e11.9) 35 16.99 144.56 8.5 (4.3e16.7)
19F 27 13.59 124.12 9.1 (4.1e20.3) 29 10.39 138.66 13.3 (5.1e34.8)
23F 22 6.54 76.53 11.7 (4.3e31.7) 28 7.72 58.51 7.6 (3.0e19.1)
Abbreviations: PCV-13, pneumococcal conjugated vaccine; PPV-23, pneumococcal polys
a Geometric mean titre ratio and 95% CI.titres did not differ. At day 365, these differences had waned (only
signiﬁcant for GMT of ELISA for serotype 6A, 1.57-fold).
Differences in antibody response after PCV-13 in PPV-23-naive
(group 2) versus PPV-23-pre-vaccinated patients (groups 3 and 4)
(Table 5)
At baseline, GMTantibody titres were signiﬁcantly lower in non-
PPV-23-pre-vaccinated patients for two (ELISA) to four (OPA) se-
rotypes versus PPV-23-pre-vaccinated patients (groups 3 and 4).
Antibody response after PCV-13 vaccination was, however, much
higher and longer lasting in the non-PPV-23-pre-vaccinated group
2 patients than in the PPV-23-pre-vaccinated groups 3 and 4 pa-
tients (ELISA: 1.68- to 4.75-fold for 12 serotypes at day 28 and 1.44-
to 3.29-fold for ten serotypes at day 365; OPA: 1.73- to 9.63-fold for
11 serotypes at day 28 and 2.43- to 7.78-fold for nine serotypes at
day 365).
Differences in antibody response after PCV-13 in patients that were
vaccinated with the PPV-23 <4 years ago (group 4) versus >4 years
ago (group 3)
At baseline and day 28, no differences were observed. At day
365, patients pre-vaccinated <4 years ago had higher GMTantibody
titre for four serotypes, but results were incongruent for ELISA
(1.52- to 1.72-fold, serotypes 7F, 14 and 19F) and OPA (1.45- to 3.47-
fold, serotypes 1, 3, 4 and 6A).
Clinical outcome
Outcome data are summarized in the Supplementary material
(Table S1). One-year mortality was 17.4%, and did not differ
signiﬁcantly among the treatment groups, although there was a
trend for lower all-cause mortality in the non-PPV-23-pre-vacci-
nated group that received a PCV-13 vaccine (p 0.055). One-yearGroup 3
PPV-23 >4 years þ PCV-13 vaccine
Group 4
PPV-23 <4 years þ PCV-13 vaccine
N GMT0 GMT4 GMT ratio (95% CI) N GMT0 GMT4 GMT ratio (95% CI)
39 0.49 0.83 1.7 (1.3e2.2) 30 0.57 1.37 2.4 (1.6e3.6)
27 0.15 0.17 1.1 (1.0e1.3) 26 0.15 0.23 1.5 (1.1e2.0)
40 0.19 0.47 2.4 (1.8e3.3) 31 0.19 0.61 3.2 (2.0e5.1)
34 1.82 2.64 1.4 (1.2e1.7) 30 1.08 1.54 1.4 (1.1e1.9)
35 0.60 1.29 2.1 (1.4e3.4) 29 0.83 2.28 2.7 (1.7e4.5)
35 0.69 1.73 2.5 (1.7e3.7) 28 0.83 1.67 2.0 (1.4e2.9)
40 1.21 1.92 1.6 (1.3e2.0) 32 0.81 1.82 2.2 (1.6e3.2)
40 0.89 1.69 1.9 (1.4e2.5) 32 0.79 1.54 1.9 (1.5e2.5)
37 1.91 3.36 1.8 (1.4e2.3) 32 2.03 4.26 2.1 (1.4e3.1)
38 1.18 2.53 2.1 (1.6e2.8) 30 0.94 2.45 2.6 (1.7e3.9)
40 2.02 4.03 2.0 (1.5e2.7) 30 1.50 2.87 1.9 (1.4e2.6)
39 0.66 1.04 1.6 (1.3e1.8) 28 0.99 1.83 1.9 (1.2e2.8)
37 0.75 1.25 1.7 (1.3e2.2) 31 0.76 1.37 1.8 (1.3e2.4)
30 9.66 21.78 2.3 (1.5e3.4) 26 9.88 26.14 2.6 (1.5e4.6)
31 8.07 12.31 1.5 (1.1e2.2) 27 8.04 13.73 1.7 (1.2e2.4)
20 23.65 149.16 6.3 (2.7e14.6) 20 36.94 256.13 6.9 (2.3e21.1)
31 11.31 36.20 3.2 (1.9e5.4) 25 12.21 47.18 3.9 (2.1e7.1)
29 42.42 316.70 7.5 (2.9e18.9) 25 32.68 352.85 10.8 (3.4e34.6)
20 107.73 378.39 3.5 (1.4e8.8) 21 51.28 265.74 5.2 (1.9e14.1)
31 48.22 217.05 4.5 (2.4e8.4) 25 45.22 240.61 5.3 (2.5e11.3)
13 66.55 258.19 3.9 (0.9e16.6) 15 52.90 302.36 5.7 (2.3e14.1)
5 46.41 98.04 2.1 (0.3e15.3) 14 145.82 314.30 2.2 (1.0e4.9)
23 44.16 154.15 3.5 (2.0e6.0) 21 31.97 184.00 5.8 (3.2e10.4)
29 63.64 205.01 3.2 (1.9e5.6) 25 37.56 102.82 2.7 (1.6e4.5)
18 27.64 71.77 2.6 (1.4e4.8) 17 31.25 114.30 3.7 (1.4e9.3)
20 12.06 56.17 4.7 (1.9e11.7) 19 11.47 38.21 3.3 (1.6e7.1)
accharide vaccine.
Table 3
Antibody response at 52 weeks compared with baseline titres
Group 1
PPV-23-naive þ PPV-23 vaccine
Group 2
PPV-23-naive þ PCV-13 vaccine
Group 3
PPV-23 >4 years þ PCV-13 vaccine
Group 4
PPV-23 <4 years þ PCV-13 vaccine
N GMT0 GMT52 GMT ratio (95% CI)a N GMT0 GMT52 GMT ratio (95% CI) N GMT0 GMT52 GMT ratio (95% CI) N GMT0 GMT52 GMT ratio (95% CI)
ELISA
1 26 0.24 0.98 4.1 (2.7e6.3) 28 0.18 0.79 4.3 (2.8e6.4) 29 0.45 0.59 1.3 (1.0e1.7) 24 0.94 1.97 2.1 (1.4e3.2)
3 18 0.11 0.14 1.3 (0.9e1.8) 19 0.12 0.14 1.2 (0.8e1.6) 21 0.14 0.14 1.0 (0.8e1.3) 18 0.15 0.21 1.4 (1.0e1.9)
4 26 0.09 0.33 3.6 (2.3e5.5) 31 0.08 0.51 6.0 (3.7e9.7) 30 0.22 0.42 1.9 (1.4e2.8) 24 0.28 0.74 2.6 (1.6e4.1)
5 27 1.23 2.36 1.9 (1.5e2.5) 30 1.20 2.62 2.2 (1.7e2.8) 27 1.80 2.09 1.2 (0.9e1.4) 23 1.50 2.33 1.6 (1.2e2.0)
6A 22 0.91 1.49 1.6 (1.3e2.1) 28 0.86 2.20 2.6 (1.8e3.6) 27 0.63 1.08 1.7 (1.1e2.6) 23 1.23 3.05 2.5 (1.5e4.0)
6B 22 0.55 1.76 3.2 (2.3e4.4) 28 0.72 2.52 3.5 (2.5e4.9) 28 0.66 1.30 2.0 (1.5e2.6) 24 1.17 2.58 2.2 (1.3e3.7)
7F 27 0.61 2.07 3.4 (2.4e4.8) 32 0.77 3.08 4.0 (2.4e6.7) 30 1.22 1.56 1.3 (1.1e1.5) 25 1.13 2.48 2.2 (1.7e2.9)
9V 27 0.49 1.15 2.3 (1.8e3.0) 30 0.73 2.25 3.1 (2.2e4.5) 30 0.98 1.39 1.4 (1.1e1.8) 25 1.12 1.94 1.7 (1.4e2.2)
14 28 1.77 7.42 4.2 (2.5e7.2) 32 1.93 9.53 4.9 (2.9e8.3) 29 2.24 2.87 1.3 (1.1e1.5) 25 2.59 4.67 1.8 (1.3e2.6)
18C 27 0.60 2.10 3.5 (2.5e5.0) 31 0.53 2.20 4.1 (2.7e6.3) 29 1.22 1.83 1.5 (1.2e1.8) 26 1.22 2.90 2.4 (1.7e3.4)
19A 27 1.61 2.83 1.8 (1.4e2.2) 31 1.57 3.62 2.3 (1.6e3.2) 30 2.36 3.45 1.5 (1.1e1.9) 26 1.89 3.39 1.8 (1.4e2.2)
19F 28 0.41 0.77 1.9 (1.4e2.5) 28 0.57 1.32 2.3 (1.5e3.5) 28 0.81 1.11 1.4 (1.2e1.6) 24 1.30 2.72 2.1 (1.4e3.1)
23F 26 0.54 1.26 2.3 (1.6e3.4) 30 1.04 2.22 2.1 (1.6e2.9) 30 0.86 1.13 1.3 (1.0e1.6) 26 0.84 1.43 1.7 (1.3e2.2)
OPA
1 26 5.62 13.69 2.4 (1.5e3.8) 27 5.72 16.66 2.9 (1.8e4.8) 22 9.02 7.66 0.8 (0.7e1.1) 22 10.83 18.71 1.7 (1.1e2.7)
3 26 4.68 6.56 1.4 (1.0e1.9) 28 6.03 8.27 1.4 (1.0e1.8) 25 10.95 10.54 1.0 (0.8e1.1) 21 8.30 11.60 1.4 (1.1e1.7)
4 17 6.62 76.37 11.5 (3.3e39.8) 22 4.82 103.90 21.5 (7.4e62.5) 19 19.45 31.44 1.6 (1.2e2.2) 18 20.45 99.88 4.9 (1.9e12.5)
5 25 4.91 8.84 1.8 (1.3e2.6) 29 5.44 21.46 3.9 (1.9e8.0) 23 15.07 21.09 1.4 (1.0e1.9) 21 10.90 17.37 1.6 (1.0e2.5)
6A 23 13.64 117.33 8.6 (3.4e21.7) 23 21.27 158.62 7.5 (3.1e17.7) 21 42.88 82.08 1.9 (1.0e3.6) 21 43.55 289.70 6.7 (2.3e19.1)
6B 15 20.42 95.35 4.7 (1.7e13.0) 24 23.19 152.79 6.6 (3.1e14.1) 18 107.32 214.08 2.0 (1.0e3.8) 17 44.28 118.99 2.7 (1.1e6.7)
7F 26 14.34 99.31 6.9 (3.1e15.2) 27 18.31 144.37 7.9 (3.3e19.0) 23 48.97 73.09 1.5 (1.0e2.3) 20 42.94 104.17 2.4 (1.2e4.7)
9V 23 21.63 54.39 2.5 (1.3e5.0) 20 36.73 90.14 2.5 (1.3e4.8) 11 85.75 142.83 1.7 (0.6e4.3) 13 35.65 109.09 3.1 (1.3e7.0)
14 17 41.69 299.01 7.2 (2.8e18.3) 21 102.33 383.09 3.7 (1.8e8.0) 3 512.48 560.25 1.1 (0.7e1.6) 11 212.08 313.74 1.5 (1.0e2.1)
18C 20 14.17 86.93 6.1 (2.8e13.5) 24 9.44 59.61 6.3 (3.0e13.3) 23 62.48 127.17 2.0 (1.3e3.2) 17 25.25 91.62 3.6 (2.0e6.7)
19A 24 13.48 29.51 2.2 (1.3e3.8) 27 18.59 81.50 4.4 (2.1e9.2) 21 92.90 100.24 1.1 (0.7e1.6) 20 45.27 53.43 1.2 (0.8e1.7)
19F 20 10.28 23.00 2.2 (1.2e4.3) 26 8.09 49.75 6.2 (2.8e13.5) 14 30.95 32.31 1.0 (0.7e1.6) 13 27.55 71.50 2.6 (1.0e6.6)
23F 20 6.53 22.83 3.5 (1.6e7.4) 25 7.30 26.00 3.6 (1.6e7.9) 21 14.33 32.62 2.3 (1.2e4.3) 16 9.46 26.80 2.8 (1.3e6.0)
Abbreviations: PCV-13, pneumococcal conjugated vaccine; PPV-23, pneumococcal polysaccharide vaccine.
a Geometric mean titre ratio and 95% CI.
Table 4
Antibody titres in PPV-23-naive patients: PCV-13 (group 1) versus PPV-23 recipients (group 2)
Antibody response at baseline Antibody response at 4 weeks Antibody response at 52 weeks
Group 1
GMT
Group 2
GMT
GMT ratioa (95% CI) Group 1
GMT
Group 2
GMT
GMT ratioa (95% CI) Group 1
GMT
Group 2
GMT
GMT ratioa (95% CI)
ELISA
1 0.20 0.20 1.04 (0.54e1.97) 1.36 1.74 1.46 (0.70e3.04) 0.96 0.86 1.03 (0.57e1.85)
3 0.11 0.12 1.08 (0.56e2.10) 0.26 0.31 1.18 (0.73e1.89) 0.17 0.15 0.90 (0.58e1.39)
4 0.09 0.10 1.05 (0.54e2.01) 0.47 1.05 2.22 (1.10e4.46)* 0.35 0.55 1.69 (0.88e3.22)
5 1.31 1.34 1.02 (0.64e1.64) 1.65 3.30 2.34 (1.54e3.55)*** 2.57 2.33 1.14 (0.79e1.64)
6A 0.83 0.95 1.15 (0.70e1.87) 1.12 2.50 2.00 (1.22e3.29)** 1.33 1.95 1.57 (1.02e2.43)*
6B 0.48 0.83 1.73 (0.86e3.48) 1.53 2.65 1.26 (0.66e2.39) 1.46 2.20 1.09 (0.69e1.75)
7F 0.61 0.79 1.30 (0.77e2.18) 2.24 6.08 2.28 (1.15e4.52)* 2.13 3.08 1.18 (0.61e2.28)
9V 0.57 0.68 1.20 (0.64e2.24) 1.53 3.00 1.85 (1.09e3.15)* 1.17 2.15 1.33 (0.86e2.06)
14 1.47 1.86 1.26 (0.70e2.27) 6.40 10.30 1.34 (0.62e2.88) 7.42 9.53 1.17 (0.56e2.48)
18C 0.60 0.63 1.05 (0.60e1.85) 2.29 3.79 1.59 (0.88e2.88) 2.01 2.20 1.18 (0.67e2.05)
19A 1.69 1.64 0.97 (0.57e1.63) 3.10 5.60 1.96 (1.19e3.22)* 2.83 3.62 1.32 (0.87e1.99)
19F 0.50 0.67 1.34 (0.71e2.53) 1.11 2.18 1.38 (0.77e2.46) 0.77 1.46 1.23 (0.75e2.03)
23F 0.58 1.04 1.78 (0.94e3.36) 1.26 2.86 1.39 (0.76e2.55) 1.16 2.15 0.91 (0.56e1.50)
OPA
1 5.5 5.5 1.00 (0.71e1.39) 47.9 56.6 1.23 (0.53e2.88) 14.3 15.3 1.20 (0.61e2.34)
3 4.5 5.9 1.33 (0.97e1.82) 27.4 16.0 0.47 (0.25e0.90)* 6.4 7.9 0.98 (0.65e1.48)
4 7.2 5.5 0.76 (0.37e1.53) 388.6 370.0 1.56 (0.30e8.08) 107.2 113.9 1.87 (0.37e9.51)
5 4.6 5.1 1.12 (0.86e1.45) 20.7 70.4 3.59 (1.47e8.75)** 11.9 19.6 2.19 (0.95e5.07)
6A 11.4 26.9 2.37 (0.92e6.09) 233.5 708.7 1.59 (0.47e5.41) 107.0 141.9 0.87 (0.24e3.08)
6B 16.1 31.0 1.93 (0.58e6.37) 454.7 897.6 1.44 (0.34e6.05) 126.8 218.5 1.41 (0.40e4.97)
7F 12.1 23.9 1.97 (0.80e4.88) 262.7 589.3 1.45 (0.45e4.65) 104.2 142.2 1.14 (0.35e3.72)
9V 41.3 29.1 0.70 (0.21e2.34) 322.5 415.9 1.10 (0.30e4.07) 64.4 77.9 0.98 (0.37e2.56)
14 38.4 98.0 2.55 (0.78e8.33) 464.8 753.8 0.54 (0.14e2.16) 223.3 402.2 0.52 (0.16e1.71)
18C 13.0 11.4 0.88 (0.37e2.07) 187.3 179.7 0.82 (0.24e2.77) 76.8 66.1 1.03 (0.35e3.05)
19A 19.4 17.8 0.92 (0.44e1.93) 114.6 128.7 1.30 (0.53e3.22) 27.5 72.6 2.00 (0.78e5.12)
19F 12.9 11.3 0.87 (0.40e1.93) 118.5 153.5 1.46 (0.42e5.14) 20.9 46.0 2.75 (0.95e7.98)
23F 7.5 7.9 1.05 (0.50e2.20) 65.4 71.4 0.65 (0.16e2.54) 25.9 30.3 1.02 (0.33e3.11)
Abbreviations: PCV-13, pneumococcal conjugated vaccine; PPV-23, pneumococcal polysaccharide vaccine.
*p <0.05; **p <0.01; ***p <0.001.
a Geometric mean titre ratio and 95% CI.
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Table 5
Baseline antibody titres in PCV-13 recipients: PPV-23-naive (group 2) versus PPV-23-pre-vaccinated (groups 3 þ 4)
Antibody response at baseline Antibody response at 4 weeks Antibody response at 52 weeks
Group 2
GMT
Group 3þ4
GMT
GMT ratioa (95% CI) Group 2
GMT
Group 3þ4
GMT
GMT ratioa (95% CI) Group 2
GMT
Group 3þ4
GMT
GMT ratioa (95% CI)
ELISA
1 0.20 0.53 0.38 (0.20e0.73)** 1.74 1.02 4.75 (2.84e7.93)*** 0.86 1.02 2.61 (1.69e4.04)***
3 0.12 0.14 0.90 (0.45e1.81) 0.31 0.21 1.68 (1.21e2.33)** 0.15 0.16 0.99 (0.69e1.43)
4 0.10 0.18 0.53 (0.29e0.96)* 1.05 0.53 3.89 (2.27e6.66)*** 0.55 0.54 2.72 (1.62e4.58)***
5 1.34 1.40 0.96 (0.57e1.61) 3.30 1.97 2.05 (1.45e2.91)*** 2.33 2.12 1.64 (1.23e2.19)**
6A 0.95 0.70 1.37 (0.84e2.22) 2.50 1.64 1.24 (0.73e2.09) 1.95 1.74 1.27 (0.78e2.07)
6B 0.83 0.68 1.22 (0.65e2.30) 2.65 1.76 1.96 (1.16e3.29)* 2.20 1.83 1.69 (1.08e2.66)*
7F 0.79 0.99 0.79 (0.45e1.40) 6.08 1.87 4.44 (2.64e7.45)*** 3.08 1.92 2.44 (1.55e3.85)***
9V 0.68 0.84 0.81 (0.45e1.45) 3.00 1.62 2.63 (1.72e4.01)*** 2.15 1.62 2.00 (1.40e2.86)***
14 1.86 1.95 0.95 (0.56e1.64) 10.30 4.10 2.89 (1.74e4.80)*** 9.53 3.88 3.29 (2.07e5.23)***
18C 0.63 1.08 0.59 (0.34e1.02) 3.79 2.37 2.66 (1.67e4.24)*** 2.20 2.13 2.22 (1.46e3.36)***
19A 1.64 1.75 0.94 (0.52e1.69) 5.60 3.49 1.84 (1.18e2.85)** 3.62 3.42 1.44 (1.01e2.03)*
19F 0.67 0.78 0.85 (0.45e1.63) 2.18 1.25 1.92 (1.23e3.00)** 1.46 1.66 1.39 (0.93e2.09)
23F 1.04 0.72 1.45 (0.82e2.54) 2.86 1.29 1.93 (1.24e3.01)*** 2.15 1.26 1.44 (1.04e2.00)*
OPA
1 5.5 9.9 0.56 (0.38e0.83)** 56.6 26.0 4.07 (2.14e7.77)*** 15.3 11.6 2.40 (1.44e4.02)**
3 5.9 8.5 0.70 (0.45e1.09) 16.0 14.4 1.73 (1.08e2.79)*** 7.9 11.1 1.20 (0.90e1.60)
4 5.5 25.2 0.22 (0.09e0.53)** 370.0 236.8 9.63 (2.79e33.26)* 113.9 66.7 7.78 (2.72e22.26)***
5 5.1 12.1 0.43 (0.25e0.72)* 70.4 42.9 4.01 (1.88e8.56)*** 19.6 19.6 2.65 (1.37e5.13)**
6A 26.9 39.8 0.68 (0.27e1.68) 708.7 431.2 3.22 (1.01e10.23) 141.9 182.2 2.09 (0.72e6.11)
6B 31.0 74.8 0.41 (0.14e1.18) 897.6 381.1 5.00 (1.57e15.89)** 218.5 174.6 2.86 (1.14e7.14)*
7F 23.9 47.8 0.50 (0.21e1.21) 589.3 246.3 5.63 (2.22e14.28)*** 142.2 96.1 4.21 (1.80e9.85)**
9V 29.1 50.4 0.58 (0.18e1.85) 415.9 248.1 2.06 (0.59e7.20) 77.9 119.8 1.06 (0.43e2.64)
14 98.0 118.9 0.82 (0.26e2.60) 753.8 250.4 4.69 (1.44e15.26)* 402.2 249.2 2.70 (1.03e7.06)*
18C 11.4 39.6 0.29 (0.12e0.68)** 179.7 163.4 3.59 (1.51e8.51)** 66.1 119.1 2.43 (1.15e5.13)*
19A 17.8 47.8 0.37 (0.19e0.74)** 128.7 148.3 2.85 (1.39e5.82)** 72.6 79.3 3.89 (1.96e7.70)***
19F 11.3 22.1 0.51 (0.24e1.07) 153.5 97.7 4.35 (1.51e12.52)** 46.0 57.5 3.80 (1.49e9.68)**
23F 7.9 12.1 0.65 (0.32e1.31) 71.4 53.2 1.92 (0.67e5.49) 30.3 42.1 1.42 (0.59e3.43)
Abbreviations: PCV-13, pneumococcal conjugated vaccine; PPV-23, pneumococcal polysaccharide vaccine.
*p <0.05; **p <0.01; ***p <0.001.
a Geometric mean titre ratio and 95% conﬁdence interval.
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treatment groups. Nine (5.8 %) patients underwent transplantation,
and four (2.6 %) were lost to follow up.
Adverse effects
Adverse effects are summarized in the Supplementary material
(Table S1). Local adverse effects, especially pain and decreased
mobility, occurred in up to one-ﬁfth of the patients, mainly during
the ﬁrst 3 days after vaccination. Local adverse effects, especially
pain, tended to be more common in the PCV-13 groups than in the
PPV-23 group. Fatigue, muscle aches and headache were common
in all patient groups.
Discussion
The current longitudinal semi-experimental phase IV trial
benchmarks antibody response after vaccination with either PPV-
23 or PCV-13 in 155 patients with ESRD treated with chronic hae-
modialysis. In non-PPV-23-pre-vaccinated patients, both PPV-23
and PCV-13 induced a signiﬁcant and durable antibody response
for 12 of the 13 antigens. Four-week antibody titres were higher in
PCV-13-vaccinated patients than in PPV-23-vaccinated patients,
but these differences grossly disappeared after 1 year. Non-PPV-23-
pre-vaccinated patients vaccinated with PCV-13 tended to have a
lower mortality than the other arms of the study. This trial was,
however, not designed to permit any conclusions on mortality. In
PPV-23-pre-vaccinated patients, PCV-13 induced an immune
response after 1 month, that partly waned after 1 year to values
that were only marginally higher than baseline values. Immune
response after PCV-13 was weaker in PPV-23-pre-vaccinated than
in non-PPV-23-pre-vaccinated patients. Local adverse effects,
especially pain, tended to be more frequent after PCV-13 than afterPPV-23. Despite vaccination against pneumococci in all patients
included in this trial, the 1-year hospitalization rate for pneumonia
was 7.1% and 1-year mortality was 17.4% in populations with ESRD.
The long-lasting antibody response in non-PPV-23-pre-vacci-
nated patients observed in this study clearly supports the guidelines
recommending universal pneumococcal vaccination in patients
with ESRD [18e21]. Although PCV-13 seems to be more immuno-
genic after 1 month than PPV-23 in non-PPV-23-immunized pa-
tients, the data in this study do not permit ﬁrm conclusions on the
preferred vaccination strategy. A future study in non-PPV-23-pre-
vaccinated patients that compares the effect of a single PCV-13
vaccination with a PCV-13 prime and PPV-23 boost strategy, as
proposed by American, French and Spanish Guidelines, would be
informative [19e21]. The weaker immune response in PPV-23-pre-
vaccinated patients may be caused by the higher dialysis vintage in
the PPV-23-pre-vaccinated groups, or by an inhibitory effect of
previous PPV-23 vaccination on the (amnestic) immune response
after PCV-13, as has been previously described [22]. This study does
not provide information on the usefulness of booster vaccination.
The differences in baseline OPA titres suggest at least some long-
lasting protective antibodies after vaccination with PPV-23.
The trial has several shortcomings. First, the trial was not
powered to detect an impact of pneumococcal vaccination with
either PPV-23 or PCV-13 vaccine on invasive pneumococcal disease
and mortality in this population, but only provides data on sec-
ondary, serological outcome measurements. Second, the trial
generated a large amount of serological data without clear guid-
ance on how to interpret them. In children, there seems to be a
good correlation between high ELISA antibody titres, high OPA
in vitro opsonophagocytic activity, and protection against experi-
mental challenge in mice. This correlation and the interpretation
of serological data are less well established in the elderly and
immunocompromised patients [1,23]. Moreover, serological cut-
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Third, where the trial design favours the generation of a large set of
comparative data in a relatively small population, it lacks the
methodological power of prospective, randomized vaccination tri-
als. Fourth, group 3 and 4 patients have a slightly higher dialysis
vintage, and represent consequently a group of patients that are
likely to have an intrinsically slightly worse prognosis than group 1
and 2 patients. However, up to now, the data generated in this study
provide the best available prospective data on pneumococcal
vaccination in patients with ESRD treated with haemodialysis.
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